GSK (NYSE:GSK) Issues FY 2025 Earnings Guidance

GSK (NYSE:GSK - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 4.250-4.590 for the period, compared to the consensus estimate of 4.360. The company issued revenue guidance of $40.7 billion-$42.7 billion, compared to the consensus revenue estimate of $32.6 billion.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. BNP Paribas started coverage on GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price objective for the company. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 24th. Finally, Morgan Stanley assumed coverage on GSK in a report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $40.58.

GSK Trading Down 0.1 %

Shares of NYSE GSK traded down $0.06 during midday trading on Monday, hitting $39.02. The stock had a trading volume of 1,104,039 shares, compared to its average volume of 5,259,188. The company's 50-day simple moving average is $37.68 and its 200 day simple moving average is $36.00. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The firm has a market cap of $80.50 billion, a P/E ratio of 24.54, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. GSK has a fifty-two week low of $31.72 and a fifty-two week high of $45.92.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. The firm had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. The company's revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.43 earnings per share. Research analysts anticipate that GSK will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be issued a dividend of $0.4216 per share. The ex-dividend date is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.32%. GSK's payout ratio is currently 86.60%.

Hedge Funds Weigh In On GSK

An institutional investor recently bought a new position in GSK stock. Brighton Jones LLC purchased a new stake in GSK plc (NYSE:GSK - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 15,604 shares of the pharmaceutical company's stock, valued at approximately $528,000. Hedge funds and other institutional investors own 15.74% of the company's stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.